Dialysis Center At West Orange is a medicare approved dialysis facility center in West Orange, New Jersey and it has 15 dialysis stations. It is located in Bergen county at 101 Old Shorts Hills Road Ste 120, West Orange, NJ, 07072. You can reach out to the office of Dialysis Center At West Orange at (973) 736-8300. This dialysis clinic is managed and/or owned by American Renal Associates. Dialysis Center At West Orange has the following ownership type - Profit. It was first certified by medicare in December, 2013. The medicare id for this facility is 312630 and it accepts patients under medicare ESRD program.
| Name | Dialysis Center At West Orange |
|---|---|
| Location | 101 Old Shorts Hills Road Ste 120, West Orange, New Jersey |
| No. of Dialysis Stations | 15 |
| Medicare ID | 312630 |
| Managed By | American Renal Associates |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 101 Old Shorts Hills Road Ste 120, West Orange, New Jersey, 07072 | |
| (973) 736-8300 | |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
| NPI Number | 1235577305 |
| Doing Business As | Dialysis Center Of West Orange Llc |
| Address | 101 Old Short Hills Rd West Orange, New Jersey, 07052 |
| Phone Number | (973) 736-8300 |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 78% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 12% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 10% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 73% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 22% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 5% | 14% |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 71% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 17% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 12% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 75% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 20% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 5% | 12% |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 87% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 13% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 83% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 7% | 12% |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
| Dialysis patients with Hemoglobin data | 54 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 26 |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 89 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 792 |
| Percentage of adult patients getting regular hemodialysis at the center | 100 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
| Adult patients getting regular peritoneal dialysis at the center | 17 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 137 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 82 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Dialysis Center At West Orange with elevated calcium levels.
| Patients with hypercalcemia | 105 |
| Hypercalcemia patient months | 963 |
| Patients with Serumphosphor | 110 |
| Patients with Serumphosphor less than 3.5 mg/dL | 7 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 38 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 34 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 16 |
| Patients with Serumphosphor greater than 7 mg/dL | 5 |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 75 |
| Patient months included in arterial venous fistula and catheter summaries | 618 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 68 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 5 |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 73 |
| Hospitalization Rate in facility | 131 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 243.6 |
| Hospitalization Rate: Lower Confidence Limit | 72.8 |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
The rate of readmission show you whether patients who were being treated regularly at Dialysis Center At West Orange were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 21.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 33.7 |
| Readmission Rate: Lower Confidence Limit | 12.3 |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Dialysis Center At West Orange get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .85 (As Expected) |
| SIR: Upper Confidence Limit | 2.05 |
| SIR: Lower Confidence Limit | .27 |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Dialysis Center At West Orange's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 58 |
| Transfusion Rate in facility | 44.2 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 122.5 |
| Transfusion Rate: Lower Confidence Limit | 18.1 |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
The rate of mortality show you whether patients who were being treated regularly at Dialysis Center At West Orange lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 256 |
| Mortality Rate in facility | 12.4 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 19.6 |
| Mortality Rate: Lower Confidence Limit | 7.4 |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago
Dialysis Center At West Orange Location: 101 Old Shorts Hills Road Ste 120, West Orange, New Jersey, 07072 Phone: (973) 736-8300 |
Total Renal Care, Inc West Orange Dialysis Location: 375 Mount Pleasant Avenue Ste 340, West Orange, New Jersey, 07052 Phone: (973) 243-7069 |
Nxstage Kidney Care West Orange Location: 445 Pleasant Valley Way, West Orange, New Jersey, 07052 Phone: (973) 413-2240 |
News Archive
A report by a presidential advisory panel urges the federal government to be more aggressive in facilitating the adoption of universal standards for sharing electronic health information and maintaining patient privacy.
Exelixis, Inc. reported longer follow-up data from a fully enrolled cohort of patients with advanced epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial. Cabozantinib shows promising activity in these patients independent of prior response to platinum-based therapies.
Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.
Parkinson's disease is one of the commonest afflictions caused by damage to the nerve cells of the brain. Patients suffer from muscular tremors and rigidity, and their movements are severely impaired.
› Verified 9 days ago